We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
多西他赛单药与培美曲塞联合顺铂二线治疗老年晚期胃癌的疗效及对患者生活质量的影响.
- Authors
陈晓东; 段琼玉; 孙宇楠; 陈威; 吴荣
- Abstract
Objective: To investigate the efficacy of docetaxel and pemetrexed combined with cisplatin as second-line therapy for advanced gastric cancer in elderly patients and its effect on the quality of life of patients, so as to provide reference for clinical medication. Methods: 120 elderly patients with advanced gastric cancer who failed first-line chemotherapy in our hospital from June 2014 to June 2017 were selected. According to the random number table method, the patients were divided into observation group and control group with 60 cases each group. The observation group was treated with pernetrexed combined with cisplatin, while the control group was treated with docetaxel alone, the two groups were treated for 3 courses. After 3 courses of treatment, the clinical efficacy of the two groups was evaluated by evaluation criteria for therapeutic efficacy of solid tumors (RECIST). According to the classification standard of common toxicity and side effects of anticancer drugs, the adverse reactions of patients in the course of treatment were counted. Quality of life scale was used to evaluate the quality of life of patients after treatment, the patients were followed up for half a year, and the survival rates of the two groups were counted. Results: The effective rate (RR) of the observation group was 30.00%, which was slightly higher than that of the control group (25.00%), but there was no significant difference between the two groups (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0 .05). After treatment, the scores of daily life, social activities, depression and anxiety in the observation group were significantly higher than those in the control group (P<O . 05). The half-year survival rate in the observation group was 71.67%, which was significantly higher than 48.33% in the control group (P<0.05). Conclusion: Compared with docetaxel monotherapy, pemetrexed combined with cisplatin second-line treatment of elderly patients with advanced gastric cancer can improve the quality of life, prolong their survival, it is safe and reliable.
- Subjects
DRUG side effects; OLDER patients; TREATMENT effectiveness; STOMACH cancer; DOCETAXEL; PEMETREXED; CISPLATIN
- Publication
Progress in Modern Biomedicine, 2020, Vol 20, Issue 2, p277
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2020.02.015